Navigation Links
Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia
Date:12/3/2010

n order to deliver new options that target specific hematologic abnormalities and mutations, it is important to understand the molecular subtypes and genetic variations associated with hematologic cancers. Pfizer Oncology has biologics and small molecules in clinical development across a number of hematologic malignancies.

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.  Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. Pfizer Oncology has biologics and small molecules in clinical development and more than 100 clinical trials underway. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time.   For more information please visit www.Pfizer.com.  

DISCLOSURE NOTICE: The information contained in this release is as of December 3, 2010. Pfizer assumes no obligation to update  forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about certain potential indications for bosutinib, an oncology product candidate, including their potential benefits and the planned timing of regulatory submissions for such indications, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development, including with regard to the pending 24-month dat
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
2. Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds
3. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
4. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
5. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
6. Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend
7. Pfizers Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
8. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
9. Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
10. Biocon and Pfizer Enter Into Global Commercialization Agreement
11. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Minn. , Sept. 17, 2014  Rebiotix Inc. announced ... the company,s lead product candidate, RBX2660 (microbiota suspension) will be ... IDWeek 2014 conference in Philadelphia from ... be presented during the poster session on Thursday, October 9, ... C. difficile Infection: 60-Day Interim Analysis of the PUNCH-CD ...
(Date:9/17/2014)... , September 17, 2014 ... 17536, has shown positive data in a Phase 2a ... neuropathy , Glenmark Pharmaceuticals today ... Ankyrin 1 (TRPA1) antagonist, GRC 17536 has shown positive ... multi-centre, proof of concept study conducted on 138 patients ...
(Date:9/17/2014)... 2014  Members of the physician IT team ... announced today that the enterprise is working with ... sharing capabilities and provide immediate cluster fail over ... addition, the Dicom Systems enterprise imaging solutions will ... to more effectively deliver the right images to ...
Breaking Medicine Technology:PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3
... CARY, N.C., March 15, 2011 Saffron ... firm providing Natural Intelligence(1) solutions for business and ... leaders to its corporate Advisory Board . ... business-technology acumen, rich global business experience, and broad ...
... XTIO2 INC . (XTI) presented ... XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM , consisting ...  Nano-Facemask . It is the world,s most effective preventive ... air and contact surfaces. The unique nanocoating protects people ...
Cached Medicine Technology:Saffron Technology Adds Seasoned Business Executives to Advisory Board 2Saffron Technology Adds Seasoned Business Executives to Advisory Board 3OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3
(Date:9/17/2014)... September 17, 2014 The Delta Dental ... to the National Children’s Oral Health Foundation: America’s ToothFairy ... NCOHF’s Orange County Oral Health Zone Program® in California. ... is engaging a range of local constituent groups and ... of severe tooth decay and its devastating effects on ...
(Date:9/17/2014)... News) -- Managing diabetes, quitting smoking, controlling high blood ... the risk for dementia -- even late in life, ... Report 2014, commissioned by Alzheimer,s Disease International, revealed that ... percent. The study noted that obesity and an inactive ... as high blood pressure. The researchers suggested ...
(Date:9/17/2014)... care system is not properly designed to meet the ... those of their families, and major changes to the ... Institute of Medicine. The 21-member committee that wrote ... integrates traditional medical care and social services and that ... for more "advance care planning" for end-of-life by individuals, ...
(Date:9/17/2014)... shown that most 18-month-olds learn an average of two ... known about how children process information to learn new ... a new study, a University of Missouri researcher has ... and a limit exists as to how many words ... parents enhance their children,s vocabularies and assist speech-language professionals ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 CarePoint Health ... when over 150 CarePoint Health employees participated in the ... the ALS Association. The event took place on ... Medical Center. CarePoint Health donated $100 to the ALS ... for a total of approximately $15,000. The Ice Bucket ...
Breaking Medicine News(10 mins):Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 2Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 3Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 4Health News:US health system not properly designed to meet needs of patients nearing end of life, says IOM 5Health News:Babies learn words differently as they age, researcher finds 2Health News:CarePoint Health Accepts the Ice Bucket Challenge 2Health News:CarePoint Health Accepts the Ice Bucket Challenge 3
... study of young U.S. teens showed that between 11 ... an alcohol brand, and those who do appear more ... susceptibility, to beginning drinking, to binge drinking, according to ... of Pediatrics & Adolescent Medicine . , Alcohol-branded merchandise ...
... (Nasdaq: AIRM ) will report financial results for ... of the market on Tuesday, March 10, 2009. The ... 2009 at 4:15 p.m. Eastern to discuss these results. ... (domestic) or (706) 643-8826 (international) or by accessing the web ...
... surgery can restore function for obese males, study finds , , ... man, the greater his hormonal changes and the worse his ... side, the study,s authors found that gastric bypass surgery can ... obesity is correlated to lower sperm count and can be ...
... is best bet, experts say , , TUESDAY, March 3 ... find new solutions to combat the growing resistance to ... , "The startling news about oseltamivir [Tamiflu] resistance should ... effort to cope with this rapidly evolving pathogen," wrote ...
... second overall and first for long-term investment and social ... Diagnostics Incorporated (NYSE: DGX ), the world,s ... again been named to FORTUNE magazine,s list of the ... the "Health Care" category of "Pharmacy and Other Services." ...
... and CEO of the New Canadian EntityWHIPPANY, N.J., March ... company, has announced today that it is establishing a ... Ltd. This company will have its headquarters in Ontario, ... sale and distribution of branded pharmaceutical products currently available ...
Cached Medicine News:Health News:Owning alcohol-branded merchandise associated with teen drinking behaviors 2Health News:Men's Sex Lives May Suffer as Waistlines Expand 2Health News:Concerted Effort Needed to Fight Drug-Resistant Flu Strain 2Health News:Concerted Effort Needed to Fight Drug-Resistant Flu Strain 3Health News:Quest Diagnostics Again Named to FORTUNE Magazine's 'World's Most Admired Companies' List 2Health News:Halo Pharmaceutical Launches a Branded Product Marketing Company in Canada 2
This CDI original designed Bra Vest incorporates Velcro® adjustable side closures to provide maximum compression to the patients breast, upper abdomen, upper and lower back....
Female Mini-VEST Seamless, Front Closure...
Male Support Brief...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Medicine Products: